MARATTO

article · International STD Research & Reviews

Seroprevalence of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human Immunodeficiency Virus (HIV) 1 and 2 Co-infection among Female Sex Workers and Female Non-sex Workers and its Associated Risk Factors in Osun State, Nigeria

Abstract

This study examines the seroprevalence and co-infection rates of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) among female female sex workers (FSWs) and the general female population in Osun State, Nigeria. Using a cross-sectional design, 182 female participants—91 FSWs and 91 non-FSWs—were randomly selected and tested for HBV, HCV, and HIV markers. Results indicated a significantly higher prevalence of HIV among FSWs (15.4%) compared to non-FSWs (4.4%), while HBV prevalence was similar in both groups (8.8% for FSWs and 7.7% for non-FSWs). No cases of HCV were identified, possibly reflecting low prevalence in this region. Notably, higher awareness and preventive behaviors among both FSWs and non-FSWs regarding STIs, with over 80% reporting knowledge of STIs, previous testing, and awareness of blood transmission. However, HBV vaccination rates are lower, particularly among FSWs (55%). The study emphasizes the need for focused public health initiatives, such as regular screening, education on HIV and HBV prevention, and easily accessible healthcare resources, to reduce the risk of infection among high-risk populations, such as FSWs, as well as more general public awareness campaigns.

Research topics

  • Hepatitis B Virus Studies
  • HIV, Drug Use, Sexual Risk
  • Hepatitis C virus research

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.9734/isrr/2025/v14i1182

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.